Services



Nutraceutical Products



Search Knowledge Base



TeleClasses & Events




The Cancer Coach



Subscribe to
     Morph2Health




Home
    
Dr. James partners with persons with cancers and other serious illnesses to construct a "whole person" roadmap leading to health and well-being. To immediately receive a free copy of my groundbreaking book, Conquer Your Fear of Cancer, click here now to sign up for a free homepage.




Behavioral Oncology Definitions -> Autologous Communications: The Autocrine/Paracrine Languages -> Autocrine human growth hormone enhancement of human mammary carcinoma cell spreading is Jak2 dependent.

Autocrine human growth hormone enhancement of human mammary carcinoma cell spreading is Jak2 dependent.

We investigated the role of autocrine production of human (h) GH in the attachment and spreading of mammary carcinoma cells in vitro. We used a previously described model system for the study of the autocrine/paracrine role of GH in which the hGH gene (MCF-hGH) or a translation-deficient hGH gene (MCF-MUT) was stably transfected into MCF-7 cells. No differences in attachment to a collagen matrix between MCF-hGH and MCF-MUT cells were observed in either serum-free medium (SFM) or medium containing exogenous hGH, 5% serum, or 10% serum. In contrast, MCF-hGH cells spread more rapidly on a collagen matrix than did MCF-MUT cells. Exogenous hGH and 10% serum interacted with autocrine production of hGH in an additive manner to increase cell spreading. MCF-hGH cells formed filipodia and stress fibers earlier than MCF-MUT cells during the process of cell spreading and possessed marked differences in morphology after spreading. MCF-MUT cells displayed uniform and symmetrical formation of stress fibers, whereas MCF-hGH cells displayed irregular and elongated stress fiber formation. The level of cytoplasmic phosphotyrosine was increased in MCF-hGH compared with MCF-MUT cells during spreading and displayed colocalization with Janus kinase 2 (JAK2). Basal JAK2 tyrosine phosphorylation was increased, and it increased further on spreading in MCF-hGH cells compared with MCF-MUT cells. Transient transfection of JAK2 complementary DNA resulted in interaction with autocrine hGH to increase the rate of cell spreading in MCF-hGH cells compared with MCF-MUT cells. Treatment with a selective JAK2 tyrosine kinase inhibitor (AG 490) reduced the rate of MCF-hGH cell spreading to the rate of MCF-MUT cell spreading. Thus, we conclude that autocrine production of hGH enhances the rate of mammary carcinoma cell spreading in a JAK2-dependent manner.

Kaulsay KK, Mertani HC, Lee KO, Lobie PE.

Department of Medicine, National University of Singapore, Republic of Singapore.

PMID: 10746665[PubMed Citation]



Homepage | About ATO | Contact ATO | Privacy Policy | Terms and Conditions
Send Questions or Comments to info@james-arond-thomas.com
Contact Dr. James Today: (734) 973-8700.

© 2001-2006 James A. Arond-Thomas, M.D. All Rights Reserved. This content may be copied in full, with copyright, contact, creation and information intact, without specific permission, when used only in a not-for-profit format. If any other use is desired, permission in writing from Dr. Arond-Thomas is required.

Disclaimer: The entire contents of this website are based upon the opinions of Dr. Arond-Thomas, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as marked. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Arond-Thomas and his community. Dr. Arond-Thomas encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional.
Arond-Thomas Online Sitemap